Company* (Symbol) | University/ Non-Profit [Scientist] | Type Of Agreement | Product Area | Details (Month) |
Agilent Technologies Inc. (NYSE:A) and Rosetta In- pharmatics Inc. (RSTA) | Center for Genomics Research at Harvard University | License | Covers the Rosetta Resolver Expression Data Analysis System, to be used by the center to analyze data from DNA chip technologies, including Affymetrix GeneChip arrays | ND (7/00) |
AlphaOne= Pharmaceuticals Inc.* | Dana-Farber Cancer Institute | Commercialization agreement | Involves the tumor sup- pressor gene for maspin, identified by DFCI to inhibit tumor cell growth, invasion and metastasis in breast and prostate cancer | ND (7/00) |
American Bio genetic Sciences Inc. (MABA) | University College of Dublin, Ireland [Ciaran Regan] | Research program extension | Five-year extension to focus on the acceleration of ABS's compound to treat Alzheimer's disease, ABS-205, and to further evaluate it as a treatment of schizophrenia | ABS is in discussions with pharmaceutical companies interested in partnering to bring the compound to the market (7/00) |
Amersham Pharma- cia Biotech (joint venture of Nycomed Amersham [NYSE:NYE] and Pharmacia Corp. [NYSE:PHA]) | Malaysian Palm Oil Board | Development collaboration | Development of better planting materials using Amersham's microarray technology | ND (8/00) |
Angiosonics Inc.* | The Cleveland Clinic Foundation (CCF) | Collaboration | Angiosonics and CCF will work to identify optimal dosing parameters for the use of therapeutic ultrasound in reducing arterial restenosis | ND (7/00) |
Antex Biologics Inc. (AMEX:ANX) | U.S. Department of the Navy | Cooperative research and development agreement | Continuation of the clinical development of Antex's Campyvax | Antex will supply vaccine and research and development support and the Navy will fund and conduct clinical trials through Phase III (8/00) |
Aquasearch Inc. (OTCBB:AQSE) and Albany Molecular Research Inc. (AMRI) | Division of Cancer Treatment and Diagnosis, National Cancer Institute | Screening agreement | NCI will screen the collaborative compound library created by the two comp- anies for anticancer activity in 60 human tumor cell lines | The library will be available to companies for screening and licensing (8/00) |
Aquila Bio- pharmaceuticals Inc. (AQLA) | Beth Israel Deacon- ess Medical Center | Technology access | Rights to antibodies that expand and activate NK T cells, which have the potential to be developed as a therapy to treat autoimmune disorders and chronic viral infections | ND (6/00) |
Aviron (AVIR) | National Institute of Allergy and Infectious Diseases, National Institutes of Health | Extended cooperative research and development agreement | Development of FluMist vaccine through June 2003; agreement began in 1995 | ND (6/00) |
AxCell Biosci- ence Corp., a unit of Cytogen Corp. (CYTO) | The Institute for Systems Biology [Leroy Hood] | Research collaboration | Effort to chart the protein-interaction changes in prostate cells that have become cancerous and to examine other forms of cancer and disease; goal is to identify cancerous and non-cancerous protein pathways to become part of AxCell's InterFunctional Proteomic Database | ISB will provide samples from its cloned DNA libraries and AxCell will use its proteomics tools to construct protein signaling pathways (7/00) |
Boston Biomedica Inc. (BBII) | National Institutes of Health Clinical Center | Cooperative research and development agreement | Development of applications for clinical diagnostic procedures using BBI's Pressure Cycling Technology | BBI provided the NIH with a BaroCycler pressure cycling instrument (8/00) |
Cambridge Inc. (OTCBB:CNSI) | Harvard University [Han Chang] | License | Covers exclusive rights to Neuregulin-2 (cerebellum-derived growth factor), which has potential in the treatment of nervous system disorders | Harvard will receive a cash pay-NeuroScience ment and future milestone payments, as well as royalties on product sales; the National Institutes of Health awarded a $100,000 grant (7/00) |
Celera Genomics (NYSE:CRA) | Australian National Health and Medical Research Council | Subscription agreement | Agreement for five Celera databases: the Human Gene Index, the Drosophila Genome Database, the Human Genome Database, the SNP Database, and the Mouse Genome Database | ND (6/00) |
Celera Genomics (NYSE:CRA) | The University of Texas Southwestern Medical Center at Dallas, University of Cincinnati and Ohio State University | Subscription agreement | Agreement for four Celera databases: the Human Gene Index, the Drosophila Genome Database, the Human Genome Database and the Mouse Genome Database | Subscription rates are based on size of institution and the number of users (7/00) |
Celgene Corp. (CELG) | National Cancer Institute | Cooperative research and development agreement | Five-year preclinical and clinical development agreement for Celgene's thalidomide analogues, including CDC-501 | ND (6/00) |
Cell Genesys Inc. (CEGE) | University of Washington | License | Patent filing covering adeno-associated viral gene therapy to the liver; Cell Genesys plans to use the gene therapy for hu- man trials of hemophilia expected to begin in 2001 | The licensed patent is jointly owned by the two entities (8/00) |
Cel-Sci Corp. (AMEX:CVM) | National Cancer Institute [Jay Berzofsky] | Cooperative research and development agreement | Joint testing of NCI's HIV peptide epitopes and CelSci's LEAPS platform technology for peptide delivery; goal is to develop an improved HIV vaccine | ND (6/00) |
Celsion Corp. (AMEX:CLN) | Duke University | Option agreement exercise | Covers rights to technology that uses focused heat to target and selectively "turn on" gene therapy and has broad potential applications in cancer | ND (8/00) |
Cepheid (CPHD) | U.S. Army Medical Research and Material Command | Expanded contract | Development of accelerated, fully automated DNA analysis systems that process and detect pathogenic spores | U.S. Army expanded funding from $1.3M to $1.9M (8/00) |
Coley Pharmaceutical Group* | Ludwig Institute for Cancer Research | Clinical research collaboration | Development and evaluation of CpG DNA based cancer products; Coley will supply clinical results and supplies and Ludwig will conduct early studies in melanoma, myeloma and renal cell carcinoma; Coley retains rights to resulting products | Ludwig will fund early clinical studies (6/00) |
Collateral Therapeutics Inc. (CLTX) | New York University | Expanded research collaboration | Covers a research and licensing agreement for the human angiogenic gene for fibroblast growth factor-4 (FGF-4), the gene used in Generx; expanded to include the study of additional forms of FGF-4 and their interaction with biological receptors | ND (8/00) |
|
||||
Cortex Pharmaceuticals Inc. (OTCBB:CORX) | Institute for the Study of Aging and the Suncoast Gerontology Center at the University of South Florida College of Medicine [Eric Pfeiffer (SGC) and Steven Johnson (Cortex)] | Research agreement | Testing of the company's Ampakine CX516 in patients with mild cognitive impairment | The institute provided $247,000 for the study, which the company will pay back if it enters a Phase III trial for Alzheimer's disease (6/00) |
Cytoclonal Pharmaceutics Inc. (CYPH) | University of California, San Diego, and University of British Columbia [Yossef Av-Gay (UCB) and Robert Fahey (UCSD)] | License | Covering worldwide rights to a new drug target for preventing drug resistance involving a system in the pathogenic bacteria, which has demonstrated its ability to detoxify antibiotics and make them ineffective | ND (7/00) |
CytoGenix Inc.* | Baylor College of Medicine | Sponsored research agreement | Study of EnzSyn, which involves direct enzymatic synthesis of genetic material in the cell; technology to be used to develop antisense therapies for breast cancer and reduction of lung inflammation and injury | ND (7/00) |
Exact Laboratories Inc.* | Creighton University [Henry Lynch] | Research collaboration | Study of non-polyposis colon cancer to help evaluate a colorectal cancer screening test | National Cancer Institute provided a $2.8M five-year grant (7/00) |
Exelixis Inc. (EXEL) | Wisconsin Alumni Research Foundation [William Dove] | License | Covers technology to enable "forward genetic" analysis in the laboratory mouse and may allow Exelixis to identify key disease genes or drug targets difficult to identify with other technologies | ND (7/00) |
Genzyme Molecular Oncology (GZMO) | The Johns Hopkins University [Kenneth Kinzler and Bert Vogelstein] | Sponsored research agreement | Discovery of 79 genes, including 14 novel genes, implicated in tumor blood vessel growth, using SAGE genomics technology | Genzyme has rights to all intellectual property developed by JHU related to the genes found (8/00) |
Genzyme Molecular Oncology (GZMO) | Laboratory Corp. of America Holdings (NYSE:LH), City of Hope Cancer and CDT Testing Inc. | License agreements | Gives LabCorp and City of Hope non-exclusive colon cancer diagnostic rights to the APC and/or MSH2 gene and gives CDT diagnostic rights to test for mutations in the p53 gene | Genzyme received an up-front license fee under each agreement and will receive royalties on each diagnostic test performed (8/00) |
Helix BioPharma Corp. (Canada; TSE:HBP) | Althea Foundation | Research collaboration | Development of new slow-release therapies for the treatment of cervical cancer, focusing on Biphasix interferon-alpha cream | Althea Foundation is supporting the research (7/00) |
Immtech International Inc. (IMMT) | University of London's School of Hygiene and Trop- ical Medicine [Simon Croft (LSHTM)], the U.S. military and Georgia State University | Collaboration | Study the activity of a series of dicationic compounds against the parasitic disease Leishmaniasis | Georgia State University scientists received a four-year grant from the National Institutes of Health; Immtech granted an undisclosed sum to the LSHTM (8/00) |
Immusol Inc.* | University of California at San Diego [Flossie Wong-Staal] | Collaboration | Identification of the anticancer gene ppan | ND (6/00) |
Incyte Genomics Inc. (INCY) | Baylor College of Medicine | Research partnership | Study gene expression and determine the role of genes in the prevention, diagnosis and treatment of cancers that affect children, using Incyte's LifeSeq Gold gene sequence database and Baylor's biological samples | The two entities will jointly own intellectual property that results, and Incyte will license it to other companies (6/00) |
Kinetek Pharmaceuticals Inc.* | Princess Margaret Hospital's Ontario Cancer Institute | License | Covers the discovery of the role of an enzyme involved in the regulation of inflammatory diseases; research focused on a gene, GSK-3beta, that produces the enzyme critical in relaying genetic information that controls early embryonic development and cell growth in adults | ND (7/00) |
Lexicon Genetics Inc. (LEXG) | Howard Hughes Medical Institute | Technology access agreement | Allows HHMI to obtain custom knockout mice, as well as mice developed using mouse ES cells from the public portion of Lexicon's OmniBank database | ND (7/00) |
Lexicon Genetics Inc. (LEXG) | The Rockefeller University and The Scripps Research Institute | Research collaboration | Development of knockout mouse-validated gene targets with potential pharmaceutical relevance for schizophrenia | Lexicon, Rockefeller and TSRI will share equally in any proceeds from joint inventions (7/00) |
MediChem Research Inc.* | Argonne National Laboratory | User agreement | Gives MediChem access to Argonne's Advanced Photon Source high brilliance X-ray beam, which allows for high speed data collection for rapid protein structure determination | ND (6/00) |
Mycota Biosciences Inc.* | McGill University [Howard Bussey, Terry Roemer and John Davison] | License | Covers technology in which fungal genomics is applied to target analysis and drug discovery and will be used in Mycota's work in Candida albicans; Mycota also licensed a drug screening technology from Stanford University and holds the right of first refusal on property to be developed in a three-year antifungal research project at McGill and Concordia universities | ND (8/00) |
Nanogen Inc. (NGEN) | Space and Naval Warfare Center | Development agreement | Nanogen will develop and refine sample preparation protocols or microelectronic chips | Center awarded the company a contract worth $1.6M over the next two years (8/00) |
Neomorphic Inc.* | The Institute for Genomic Research | Research collaboration | To begin the second phase of development on the company's Annotation Station system, focusing on improving core capabilities to increase abilities to integrate disparate data | ND (8/00) |
Neurobiological Technologies Inc. (NTII) | University of California, Berkeley | License option | Patents on corticotopin- releasing hormone (CRH) analogs; includes a work plan for in vivo models of the hormones to screen CRH-analogs; NTI holds an orphan drug designation for Xerecept, a synthetic preparation for CRH, which may reduce brain swelling in peritumoral brain edemas | ND (8/00) |
Northwest Biotherapeutics Inc.* | The Regents of the University of California [Arie Belldegrun and Cho-Lea Tso (UCLA)] | License option | Option to secure rights to a kidney cancer tumor-specific antigen (GM-CSF/G250) to be used with the company's dendritic cell-based immunotherapy for cancer | ND (7/00) |
NsGene A/S* (Denmark) | Denmark's Technical University (DTU) | Collaboration and license agreement | Research and development of bioinformatics tools for searching Human Genome Project data for new genes that can guide the development of immature neural stem cells into various specialized nerve cells | DTU retains all rights to methods developed and will receive royalties on products commercialized; NsGene gains rights to novel genes with therapeutic applicability in the central nervous system and will fund the collaboration (8/00) |
Oncology Sciences Corp.* | AMC Cancer Research Center | Establishment of a new company | OSC will pursue research and development techniques to find novel and non-toxic cancer therapies, specifically in the areas of prostate, brain and skin cancers | ND (6/00) |
Panacea Pharmaceuticals Inc.* | Case Western Reserve University [Mark Smith] | Collaborative research and licensing agreement | Covers drug development using cell cycle abnormalities found in Alzheimer's disease; gives the company exclusive worldwide rights to the technology and all future development through the working collaboration | ND (7/00) |
PE Biosystems (NYSE:PEB) | Ludwig Institute for Cancer Research | Development collaboration | Development of a proteomic informatics infrastructure that will allow biologists to handle all aspects of parallel, complex collaborative experiments in cancer | ND (7/00) |
PPGx Inc.* | Bioinformatics Research Center at North Carolina State University | Development collaboration | Development and implementation of statistical methodologies to speed and enhance the analysis and interpretation of pharmacogenomic data; a first task will be to characterize the inherent variation in readings from micro arrays | ND (8/00) |
Prospect Genomics Inc.* | Rockefeller University [Andrej Sali] | License | Covers three-dimensional protein structure models for more than 0.2M protein sequences and the automated high throughput system used to create the database | Prospect will provide the structures to academic researchers and license the database commercially (8/00) |
Scriptgen Pharmaceuticals* | The European Molecular Biology Laboratory | Formation of a new company | Anadys Pharmaceuticals will focus on discovery, development and commercialization of new medicines to treat infectious disease using technologies derived from Scriptgen, EMBL, the Scripps Research Institute, and the University of California | Anadys was created through the issuance of Scriptgen shares (6/00) |
Select Therapeutics Inc. (OTC BB: SLPU) Senomyx Inc.* | University of Arizona Cancer Center [Evan Hersh] Rockefeller University [Peter Mombaerts] | Research agreement License | To evaluate therapeutic vaccines for cancer patients Covers a candidate human pheromone receptor gene, VIRL1 | ND (8/00) |
Sequenom Inc. (SQNM) | Public Health Research Institute and the National Institutes of Health | Research collaboration and grant | Development of high-speed diagnostic tests to identify multidrug-resistant M. tuberculosis strains | Results of the study will be placed in the public domain on the NCI web site (8/00) |
Sequenom Inc. (SQNM) | The University of Texas South- western Medical Center at Dallas | Research and development collaboration | The three-year collaboration will focus on identifying single nucleotide polymorphisms useful for improving diagnosis and therapy of cardiovascular diseases | The company and university will share the intellectual property that results (8/00) |
Sequenom Inc. (SQNM) | GSF-National Research Center for Environment and Health | Purchase and license agreement | Covers Sequenom's MassARRAY technology to perform large-scale single nucleotide polymorphism validation projects, including candidate gene associations and genetic epidemiology | ND (7/00) |
SignalGene Inc. (Canada; TSE:SGI) and Ecogenix Inc.* | Sainte-Justine Hospital, the Mother and Child University of Montreal Health Center | Research alliance | A three-year research program aimed at identifying human gene variants that determine drug metabolism and response to drug therapy, including chemotherapy; Ecogenix was formed under the alliance; SignalGene also acquired intellectual property related to the method for analysis of gene variants of drug metabolism enzymes for C$0.45M | SignalGene will invest C$0.1M (US$68,000) per year over three years in Ecogenix, and T2C2/Bio Limited Partnership will invest $0.4M per year in the new company; investment proceeds will fund the three-year research program (6/00) |
Symyx Technologies Inc. (SMMX) | The Instituto Mexicano Del Petroleo | Purchase agreement | IMP will purchase a second module of Symyx's Discovery Tools hetero- geneous catalysis system, expanding its rapid screen- ing capabilities | ND (7/00) |
Vion Pharmaceuticals Inc. (VION) | Memorial Sloan- Kettering Cancer Center [Ronald Blausberg] | Research collaboration | Study of the use of Vion's tumor amplified protein expression therapy (TAPET) bacterial vector technology for the diag- nostic imaging of tumors | The National Cancer Institute awarded a $0.14M research contract to the joint effort (8/00) |
Viragen Inc. (AMEX:VRA) and its subsidiary Viragen Ltd. | University of Nottingham and Cancer Research Campaign Technology [Lindy Durrant and Ian Spendlove] | Development agreement | Development of a new cancer vaccine therapy for breast, ovarian and colorectal cancers | Work will take place primarily at the CRC Department of Clinical Oncology at the University of Nottingham, England, where the technology originated (7/00) |
Notes: This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers. |
||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-The-Counter Bulletin Board; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange |
||||
Unless otherwise noted, the stock symbols listed are on the Nasdaq market. * Privately held company ND = Not disclosed. |
||||
To read more on related topics, click on one of the words below.